Home Featured Page 253

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint...

PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the...

COMPASS Pathways launches proposed public offering

Mystical Encounters, With and Without Drugs

How To Talk With Your Kids About Psychedelics

Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to...

Red Light Holland and Halo Collective Create Red Light Oregon, Inc....

Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in...

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands...

Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec...

1...252253254...295 Page 253 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint...

PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the...

COMPASS Pathways launches proposed public offering

Mystical Encounters, With and Without Drugs

How To Talk With Your Kids About Psychedelics

Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to...

Red Light Holland and Halo Collective Create Red Light Oregon, Inc....

Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in...

Bright Minds Biosciences Appoints Industry Experts for Key Roles and Expands...

Awakn Life Sciences Initiates New Chemical Entity Development Program with Evotec...

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY